MTOR and myelodysplastic syndrome: Our multi-omics results support therapeutic strategies that suppress the STAT3 pathway (e.g., JAKi), enhance protein translation (e.g., NGF and EGF treatments), activate the mTOR pathway, and restore the SAM/SAH methylation index (e.g., betaine treatment) as a means to improve multiple symptoms of MDS patients.